Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Chemed Corporation’s (NYSE: CHE) SEC filings, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Chemed is a Delaware-incorporated holding company headquartered in Cincinnati, Ohio, operating VITAS Healthcare and Roto-Rooter as wholly owned subsidiaries.
For investors analyzing Chemed’s hospice operations, filings and related exhibits can offer detail on VITAS Healthcare’s net patient revenue, average daily census, admissions, and the impact of Medicare reimbursement rates and Medicare Cap billing limitations. Management’s discussion of these topics in earnings releases, which are often furnished as exhibits to Form 8-K, helps explain how regulatory and reimbursement factors influence segment performance.
Filings also shed light on Roto-Rooter’s plumbing, drain cleaning, water restoration, and water cleanup services. Segment disclosures in attached earnings releases describe revenue trends across commercial and residential customers, gross margins, selling, general and administrative expenses, and adjusted EBITDA margins. These details help readers understand how demand for plumbing and drain cleaning services affects Chemed’s consolidated results.
Chemed’s SEC filings may address capital structure and capital allocation, including its Amended and Restated Credit Agreement, share repurchase authorizations, and long-running dividend program. They can also disclose material events such as updates to earnings guidance, executive leadership changes, or other significant corporate developments.
On this page, AI-powered tools summarize lengthy filings and attached press releases, highlighting items such as quarterly earnings (often reported via Form 8-K), non-GAAP measures like EBITDA and Adjusted Diluted EPS, and regulatory or reimbursement disclosures relevant to VITAS and Roto-Rooter. Users can also review insider- and management-related information when it appears in current reports or other SEC documents.
CHEMED CORP president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock in an open-market transaction at a weighted average price of $403.18 per share. Following this sale, he directly holds 93,719 shares. The trade was executed through multiple transactions at prices between $399.31 and $404.68.
Chemed Corporation reports a Form 144 notice reflecting proposed sales of Common Stock by Kevin McNamara related to stock awards and exercises. The filing lists award/exercise events dated 02/17/2023, 05/01/2023, and 05/02/2023, including awards of 492 and 498 shares.
Chemed Corporation operates two main businesses: VITAS hospice and palliative care and Roto-Rooter plumbing and restoration services, all managed in a decentralized structure. VITAS generates over 95% of its revenue from Medicare and Medicaid per-diem payments, making government reimbursement policies critical to its results.
The filing highlights extensive regulatory oversight, including hospice Conditions of Participation, anti-kickback and false-claims rules, licensing and Certificate of Need laws, and evolving privacy and cybersecurity requirements. VITAS previously operated under a five-year corporate integrity agreement that concluded in 2023, and in 2025 experienced a cyberattack in which a threat actor accessed protected health information.
Roto-Rooter faces fragmented but intense competition and is sensitive to weather-driven demand and labor availability for licensed plumbers. As of December 31, 2025, Chemed employed 15,811 people and emphasized safety, training and retention programs. Recent growth initiatives included multiple small Roto-Rooter franchise purchases and VITAS’s $85.0 million cash acquisition of Covenant hospice operations and an assisted living facility.
Chemed Corporation reported mixed fourth-quarter 2025 results and issued 2026 guidance. Q4 service revenues and sales were $639.3 million, essentially flat year over year, while net income declined to $76.8 million from $90.3 million. Diluted EPS fell to $5.48 from $6.02.
VITAS net revenue grew 1.9% to $418.8 million, supported by higher days-of-care and Medicare reimbursement, though gross margin excluding Medicare Cap fell to 27.3%. Roto-Rooter revenue declined 3.7% to $220.6 million, and adjusted EBITDA dropped 21.1% with margin down to 21.5%.
For full-year 2025, Chemed generated service revenues and sales of $2.53 billion and net income of $265.2 million, or $18.34 diluted EPS. Adjusted diluted EPS was $21.55. The company ended 2025 with $74.5 million in cash, no debt, and repurchased 400,000 shares for $174.6 million.
Management expects 2026 VITAS revenue to grow 5.5%–6.5% before Medicare Cap and Roto-Rooter revenue to grow 3.0%–3.5%. Adjusted diluted EPS is projected between $23.25 and $24.25, above 2025’s $21.55, with about 55% of adjusted earnings and EBITDA weighted to the year’s second half.
Chemed Corp executive vice president Spencer S. Lee reported PSU vesting, share issuance, tax withholding, and a new equity award. On February 13, 2026, 499 shares of Chemed capital stock were acquired through derivative exercises at $469.56 per share, with 154 shares withheld to cover taxes, leaving 14,912 shares of capital stock held directly.
Two tranches of 402 performance stock units each were exercised at $0, with 1,966 and 1,564 PSUs remaining after the respective transactions. Lee also received a new grant of 960 PSUs, bringing direct PSU holdings to 2,524. One PSU award tied to cumulative adjusted EPS paid out at 124.1% of target based on $67.67 performance versus a $66.46 maximum threshold, while a separate PSU award tied to relative total shareholder return paid out at 0% of target.
Chemed vice president and director Thomas C. Hutton reported equity compensation activity, not open-market trading. On February 13, 2026, he exercised performance stock units (PSUs) into 199 shares of capital stock at $469.56 per share and had 72 shares withheld to cover tax obligations tied to vesting.
The PSUs that vested were based on Chemed’s cumulative adjusted earnings per share from January 1, 2023 through December 31, 2025, where actual performance of $67.67 exceeded the maximum payout threshold of $66.46, producing an award above target. A separate PSU tranche tied to relative total shareholder return over the same period paid out at 0% of target. Hutton also received a new grant of 374 PSUs that can vest over the 2026–2028 performance period.
Chemed Corp CEO Joel L. Wherley reported equity compensation activity tied to performance stock units on February 13, 2026. He acquired 273 shares of capital stock through the exercise of PSUs at an exercise price of $469.56 per share and had 852 shares of capital stock directly owned afterward. The company’s cumulative adjusted earnings per share of $67.67 for the 2023–2025 period exceeded the $66.46 maximum payout threshold, resulting in a PSU payout of 123% of target, or 124.1% including dividend reinvestment. A separate PSU award based on relative total shareholder return for the same period paid out at 0% of target.
Chemed Corporation’s VP & Chief Financial Officer Michael D. Witzeman reported equity compensation activity tied to performance stock units (PSUs). On 02/13/2026, 413 shares of capital stock were issued at $469.56 per share from PSU vesting, with 120 shares withheld to cover taxes, leaving 5,953 shares directly owned.
The PSU vesting was driven by performance from January 1, 2023 through December 31, 2025. Cumulative adjusted EPS of $67.67 exceeded the maximum payout threshold of $66.46, producing an award at 123% of target, or 124.1% including dividend reinvestment. A separate PSU tranche tied to relative total shareholder return over the same period paid out at 0%, including dividends. Witzeman also received a grant of 1,394 new PSUs that can each convert into one share of capital stock based on performance from January 1, 2026 to December 31, 2028, with final performance determined by March 15, 2029.
Chemed Corp director and president/CEO Kevin J. McNamara reported equity compensation activity involving performance stock units and company shares. On February 13, 2026, performance stock units (PSUs) vested and were settled in 2,714 shares of capital stock at $469.56 per share, with 1,192 shares withheld to cover tax obligations.
The vested PSUs tied to cumulative adjusted earnings per share from January 1, 2023 through December 31, 2025, where actual performance of $67.67 exceeded the maximum payout threshold of $66.46, yielding an award of 123% of target, or 124.1% of target including reinvested dividends. A separate PSU tranche based on relative total shareholder return over the same period earned 0% of target, even after dividend reinvestment.
McNamara also received a new grant of 5,114 PSUs that will vest based on performance targets over January 1, 2026 to December 31, 2028, with the performance level to be determined by March 15, 2029 and any earned shares delivered thereafter.